

**EXHIBIT B**  
**A MARKED UP VERSION OF THE**  
**CLAIMS AMENDED ON JUNE 18, 2002**  
**IN U.S. APPLICATION SERIAL NO.: 09/610,118**  
**ATTORNEY DOCKET NO.: 7853-211**

---

132. (Amended) A substantially purified antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, wherein said antibody immunospecifically binds to a human TANGO 268 antigen.

140. (Amended) The antibody of claim 138 [or 139], further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

144. (Amended) The antibody of claim [143] 142, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

148. (Amended) The antibody of claim [147] 146, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

152. (Amended) The antibody of claim 150 [or 151], wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

159. (Amended) The antibody of claim 157 [or 158], wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by

the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

245. (Amended) The antibody of claim [244] 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2443.

246. (Amended) The antibody of claim [244] 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

247. (Amended) The antibody of claim [244] 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2445.

254. (Amended) A substantially purified antibody that competes with a scFv antibody encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442 for binding to a human TANGO 268 antigen.

256. (Amended) The antibody of claim [137] 132, 133 or 134, wherein the antibody is a monoclonal antibody.

257. (Amended) The antibody of claim [137] 132, 133 or 134, wherein the antibody is a human antibody.

258. (Amended) The antibody of claim [137] 132, 133 or 134, wherein the antibody is a humanized antibody.

259. (Amended) The antibody of claim [137] 132, 133 or 134, wherein the antibody is a Fab fragment.

260. (Amended) The antibody of claim [137] 132, 133 or 134, wherein the antibody is an scFv.

261. (Amended) The antibody of claim [137] 132, 133 or 134, wherein the antibody is conjugated to a therapeutic or drug moiety.

262. (Amended) The antibody of claim[137] 132, 133 or 134, wherein the antibody is conjugated to a detectable substance.

263. (Amended) A pharmaceutical composition comprising the antibody of claim [137] 132, 133 or 134 and a pharmaceutically acceptable carrier.

264. (Amended) A kit comprising the antibody of claim [137] 132, 133 or 134 and instructions for use, in one or more containers.